China Pharma Holdings (CPHI) Other Non-Current Liabilities (2010 - 2023)

China Pharma Holdings has reported Other Non-Current Liabilities for 10 years, with the latest figure at $2.2 million in Q1 2023.

• For the quarter ending Q1 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2023 stood at $2.2 million (changed N/A YoY), and the FY2022 full-year result was $2.4 million, up 26.85% from the prior year.
• Other Non-Current Liabilities for Q1 2023 stood at $2.2 million, down from $2.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $3.1 million in Q2 2021, with the low at $1.7 million in Q3 2021.
• Historically, Other Non-Current Liabilities has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities slumped 31.44% — and 2022, when it gained 26.85%.
• China Pharma Holdings' Other Non-Current Liabilities stood at $2.4 million in 2019, then increased by 14.44% to $2.7 million in 2020, then tumbled by 31.44% to $1.9 million in 2021, then advanced by 26.85% to $2.4 million in 2022, then declined by 9.15% to $2.2 million in 2023.
• The last three Other Non-Current Liabilities figures came in at $2.2 million (Q1 2023), $2.4 million (Q4 2022), and $1.9 million (Q4 2021), per Business Quant data.